← ANALYST RATINGS · TIPRANKS
Exelixis (EXEL): analyst forecast and price target
Analyst consensus
Hold3 Buy8 Hold1 Sell
Ratings of 12 analysts in the last 3 months · top analysts only12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $52.30, the highest $64.00, the lowest $41.00. The average is −16.0% from the last price of $62.23.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $72.00 → $71.00−1.4% | Buy | +14.1% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $72.00 → $71.00−1.4% | Buy | +14.1% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $73.00 → $72.00−1.4% | Buy | +15.7% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $65.00 → $71.00+9.2% | Buy | +14.1% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $66.00 → $72.00+9.1% | Buy | +15.7% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $68.00 → $74.00+8.8% | Buy | +18.9% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $41.00 | Sell | −34.1% | Reiterated | 09.10.26on TipRanks 09:10 | +0.8%next day 0.0% · 5 days +5.9% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $45.00 → $51.00+13.3% | Hold | −18.0% | Reiterated | 08.10.26on TipRanks 09:05 | +1.4%next day +0.8% · 5 days +6.7% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $52.00 → $54.00+3.8% | Hold | −13.2% | Reiterated | 07.10.26on TipRanks 09:10 | +0.4%next day +1.4% · 5 days +5.3% | ↗ |
| David Lebowitz★★★★★★★★★★#597 · hits 60% · avg +14.2% | Citi | $54.00 | Hold | −13.2% | Reiterated | 11.09.26on TipRanks Sep 14 10:45 | −3.1%next day +0.6% · 5 days +4.1% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | — | Hold | — | Reiterated | 11.09.26on TipRanks Sep 12 13:45 | −3.1%next day +0.6% · 5 days +4.1% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Buy | — | Reiterated | 11.09.26on TipRanks 10:26 | −3.1%next day +0.6% · 5 days +4.1% | ↗ |
| Unknown Analyst | Guggenheim | — | Hold | — | Reiterated | 01.09.26on TipRanks 09:55 | +4.8%next day +2.4% · 5 days +2.4% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $52.00 | Hold | −16.4% | Downgrade | 06.08.26on TipRanks 13:50 | −7.8%next day +3.0% · 5 days −4.3% | ↗ |
| Eva Fortea Verdejo★★★★★★★★★★#231 · hits 80% · avg +54.1% | Wells Fargo | $49.00 → $50.00+2.0% | Hold | −19.7% | Assigned | 06.08.26on TipRanks 07:10 | −7.8%next day +3.0% · 5 days −4.3% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $53.00 | Hold | −14.8% | Reiterated | 06.08.26on TipRanks 07:10 | −7.8%next day +3.0% · 5 days −4.3% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $49.00 | Hold | −21.3% | Reiterated | 06.08.26on TipRanks 04:16 | −7.8%next day +3.0% · 5 days −4.3% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $64.00 | Buy | +2.8% | Reiterated | 05.08.26on TipRanks Aug 6 10:54 | +1.5%next day −7.8% · 5 days −11.5% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $55.00 | Buy | −11.6% | Reiterated | 05.08.26on TipRanks Aug 6 06:00 | +1.5%next day −7.8% · 5 days −11.5% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $43.00 → $52.00+20.9% | Hold | −16.4% | Assigned | 02.07.26on TipRanks 08:55 | +3.6%next day −1.4% · 5 days −0.2% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $56.00 | Buy | −10.0% | Reiterated | 02.07.26on TipRanks 06:30 | +3.6%next day −1.4% · 5 days −0.2% | ↗ |
| Unknown Analyst | Jefferies | $47.00 | Buy | −24.5% | Reiterated | 25.03.26on TipRanks 12:55 | +2.4%next day +0.8% · 5 days +3.2% | ↗ |
| Unknown Analyst | Stephens | $60.00 | Buy | −3.6% | Reiterated | 11.02.26on TipRanks 07:28 | −0.1%next day +1.0% · 5 days +3.9% | ↗ |
| Unknown Analyst | Wolfe Research | — | Hold | — | Initiated | 17.11.25on TipRanks 16:30 | +1.4%next day −1.6% · 5 days −1.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Exelixis
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 07.10.26: target $51.80 at a price of $58.33 (−11.2%); now: $52.30 at $62.23 (−16.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 4 | 5 | 4 | 4 | 2 |
| Hold | 16 | 13 | 14 | 18 | 20 | 15 |
| Sell | 0 | 1 | 1 | 2 | 2 | 3 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.88 (from $0.76 to $0.96). Last quarter: $0.91.
Sales
Next quarter’s sales estimate — $647M (from $631M to $668M). Last quarter: $629M.
Best top-analyst consensus in the sector · Healthcare
About Exelixis
- CEO: Michael Morrissey
- Employees: 1,077
- 1851 Harbor Bay Parkway, Alameda, CA, 94502, US
- www.exelixis.com
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, th
Data from the stock’s TipRanks forecast page, read 28 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗